JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M100031200 on May 24, 2001

J. Biol. Chem., Vol. 276, Issue 29, 27152-27158, July 20, 2001
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
276/29/27152    most recent
M100031200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Spiegelman, V. S.
Right arrow Articles by Fuchs, S. Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Spiegelman, V. S.
Right arrow Articles by Fuchs, S. Y.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Induction of beta -Transducin Repeat-containing Protein by JNK Signaling and Its Role in the Activation of NF-kappa B*

Vladimir S. SpiegelmanDagger , Pete Stavropoulos§, Esther Latres, Michele Pagano, Ze'ev Ronai§, Tomas J. SlagaDagger , and Serge Y. Fuchs||**

From the Dagger  AMC Cancer Research Center, Lakewood, Colorado 80214, § Ruttenberg Cancer Center, Mount Sinai School of Medicine, New York, New York 10029, the  Department of Pathology, New York University, New York, New York 10016, and the || Department of Animal Biology, University of Pennsylvania, Philadelphia, Pennsylvania 19104

Received for publication, January 2, 2001, and in revised form, May 9, 2001


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Activation of Jun N-kinase (JNK) and NF-kappa B transcription factor are the hallmarks of cellular response to stress. Phosphorylation of NF-kappa B inhibitor (Ikappa B) by respective stress-inducible kinases (IKK) is a key event in NF-kappa B activation. beta -TrCP F-box protein mediates ubiquitination of phosphorylated Ikappa B via recruitment of SCFbeta -TrCP-Roc1 E3 ubiquitin ligase complex. Subsequent proteasome-dependent degradation of Ikappa B results in activation of the NF-kappa B pathway. We found that a variety of cellular stress stimuli induce an increase in the steady state levels of beta -TrCP mRNA and protein levels in human cells. Activation of stress-activated protein kinases JNK (and, to a lesser extent, p38) by forced expression of constitutively active mutants of JNKK2 and MKK6 (but not MEK1 or IKKbeta ) also leads to accumulation of beta -TrCP. Transcription of the beta -TrCP gene is not required for JNK-mediated induction of beta -TrCP. A synergistic effect of stimulation of IKK and JNK on the transcriptional activity of NF-kappa B was observed. The mechanisms of beta -TrCP induction via stress and its role in NF-kappa B activation are discussed.


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

The survival of living organisms depends on the promptness and efficiency of their response to adverse changes in the environment. Eukaryotic cellular responses to stress involve immediate post-transcriptional events within the maze of signal transduction pathways (1). Activation of these pathways often leads to further changes in gene expression and de novo synthesis of proteins that exert a protective effect on the cell. Whereas tremendous progress has been achieved in identification and characterization of key regulatory elements of separate signaling pathways, the complexity of coordination between simultaneously induced and transduced signals and the role of these interactions in the outcome of signaling are largely underestimated and yet to be understood.

Activation of the stress-activated protein kinases (c-Jun N-terminal kinases (JNK)1 and p38 kinases) and Ikappa B kinases (IKK) followed by AP1/ATF- and NF-kappa B-dependent transcription orchestrates the rapid cellular response to a wide spectrum of exogenous and endogenous stress-induced agents. These pleiotropic mediators of stress-induced gene expression play a critical role in cell growth and differentiation, apoptosis, and adaptive responses to changes in cellular redox balance (reviewed in Refs. 2 and 3).

The JNK and p38 pathways are preferentially activated by a diverse array of cellular stresses including UV light, x-rays, hydrogen peroxide (H2O2), heat and osmotic shock, and withdrawal of growth factors. JNK are activated via upstream phosphorylation by two distinct JNKKs, JNKK1/MKK4/SEK1 (4, 5) and JNKK2/MKK7 (6, 7). The p38 subgroup is phosphorylated by MKK3, MKK4 (4), and MKK6 (8, 9). Eleven different kinases capable of phosphorylating JNK and p38 kinases (including MEKK1-4, ASK1 and -2, TAK1, and others) have been identified as upstream activators of the JNK/p38 pathway (reviewed in Ref. 2). The precise mechanisms of their activation by stress are not yet comprehended in full. The outcome of JNK/p38 signaling is stress-inducible phosphorylation-dependent activation of their substrate proteins, which include transcription factors (c-Jun, ATF2, Elk1, etc.), apoptosis regulators (Bcl2, Bid, etc.), and other effectors. Modulation of gene expression due to an increase in transactivation potential and protein stability of proteins phosphorylated by JNK/p38 are among the mechanisms of JNK/p38-mediated effects. Recent evidence for the role of JNK/p38 kinases in stabilization of the short lived mRNAs of cytokines and growth factors (10-14) represents yet another mode of the regulation by stress-activated protein kinases, although the effector proteins, which mediate mRNA stabilization, are largely unknown.

NF-kappa B is a dimeric transcription factor composed of members of the Rel family. A large number of stress stimuli including UV irradiation, ionizing radiation, viral infection, and reactive oxygen species can activate NF-kappa B and its target genes. These target genes include those involved in the immune response, inflammatory response, cell adhesion, cell growth, and apoptosis. The activity of NF-kappa B is tightly regulated at the level of its localization by a family of inhibitory proteins, Ikappa Bs, that sequester NF-kappa B in the cytoplasm of unstimulated cells. Ubiquitin-dependent degradation of Ikappa Bs in response to stress results in the nuclear translocation and transcriptional activity of NF-kappa B (reviewed in Ref. 15).

Most of the stress stimuli, which induce NF-kappa B, trigger a cascade of events resulting in the activation of Ikappa B kinases (IKK). IKK is a large (>700-kDa) multicomponent enzyme complex containing two closely related kinase subunits with identical structural domains, IKKalpha (IKK1) and IKKbeta (IKK2), and two accessory proteins, IKKgamma and IKAP (reviewed in Ref. 3). Two members of the MAP kinase family, NF-kappa B-inducing kinase (NIK) and MEKK1, have been shown to directly interact with IKK and activate the kinase subunits in experiments based on overexpression of the recombinant proteins. The requirements of NIK and MEKK1 for activation of IKK by the relevant physiological stimuli have not been proven, and the upstream kinases in this signaling pathway remain to be identified (reviewed in Ref. 3). As an outcome of their activation, IKK mediate phosphorylation of Ikappa B on two critical serine residues (e.g. serines 32 and 36 in Ikappa Balpha , serines 19 and 23 in Ikappa Bbeta , and serines 18 and 22 in Ikappa Bepsilon ).

This phosphorylation serves as a recognition signal for seven WD40 repeats located at the carboxyl-terminal domains of beta -TrCP (16) and HOS/Fbw1b proteins (17). Binding of beta -TrCP/Fbw1a (or its close relative HOS/Fbw1b) proteins to Ikappa B mediates Ikappa B ubiquitination (and subsequent 26S proteasome-dependent degradation) through recruitment of the SCFbeta -TrCP-Roc1 E3 ubiquitin ligase (reviewed in Refs. 18-20). These proteins belong to a large family of ubiquitin ligase receptors containing the 42-48-amino acid F-box motif, which is required for binding to the protein Skp1 (21-23). Skp1 recruits beta -TrCP/Fbw1a with Cdc53/cullin 1 and Roc1/Rbx1, thereby allowing the SCF E3 ubiquitin ligase to tether ubiquitin-conjugating enzymes (reviewed in Ref. 18).

Both phosphorylation of Ikappa B and beta -TrCP binding are required for Ikappa B ubiquitination and degradation. Inhibition of beta -TrCP/HOS function by expression of a dominant negative mutant abrogates the degradation of Ikappa B phosphorylated by the activated IKK (17, 24-30). The endogenous levels of beta -TrCP are low. These levels can be up-regulated in some cells by the activation of the Wnt/beta -catenin/Tcf signaling pathway, resulting in the activation of NF-kappa B-dependent transcription (31). Interestingly, although the functional Tcf was apparently required for up-regulation of beta -TrCP, we have failed to completely inhibit the effect of Wnt (but not beta -catenin) on beta -TrCP levels by co-expression of the dominant negative Tcf4. Moreover, it was consistently observed that expression of Wnt was more efficient in the increase in beta -TrCP levels and NF-kappa B transcriptional activity as compared with expression of the stable beta -catenin mutant (31). Since it has been shown that Wnt exerts some of its effects in a beta -catenin-independent manner via the JNK pathway (32), we investigated whether the activation of JNK signaling can actually regulate the abundance and activity of beta -TrCP.

In this study, we first demonstrate that cellular stress and induction of stress-activated protein kinases increase the levels and activities of beta -TrCP via stabilization of beta -TrCP mRNA. These data provide a mechanism for the positive cooperation between activated JNK and IKK in regulating the NF-kappa B transcriptional activity in response to cellular stress.

    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Plasmids-- The constitutively active IKKbeta S177E,S181E (IKKSE), 2x-kappa B-luciferase and glutathione S-transferase-Ikappa B expression vectors (33, 34), constitutively active JNKK2 (JNKKCAA) and its inactive counterpart (JNKKAA), and constitutively active MKK6 (MKK6D/D; Ref. 10) were a generous gift of M. Karin. Constitutively active MEKK1 (Delta MEKK1) and dominant negative SEK1/MKK4 (SEKAL) were kindly provided by A. Minden and J. Woodgett. The expression vector for constitutively active MEK1 (MEKEL) was a kind gift of S. Aaronson. beta -TrCP expression vector containing the 3'-untranslated region (3'-UTR) was a gift of R. Benarous (16).

Antibodies-- Monoclonal antibodies against FLAG tag (M2; Sigma), MEKK1 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA), and SEK1 (New England Biolabs) were purchased. Polyclonal antibodies against beta -TrCP were raised by Zymed Laboratories Inc. against synthetic peptide encompassing amino acid residues NSSEREDCNNGEPPRKIIPEKNSLRQTY of beta -TrCP and purified via a peptide affinity column.

Northern Blot and Nuclear Run-on Analyses-- Twenty µg of total RNA isolated from freshly harvested cells using TRI-reagent (Molecular Research Center, Cincinnati, OH) was subjected to Northern blotting analysis using random primer-labeled probes for human beta -TrCP. The membranes were stripped and rehybridized with a probe to 7S RNA to verify that equal amounts of RNA were loaded and transferred. A nuclear run-on assay was performed as previously described (31).

Transfections, Immunoblotting, and Reporter Assays-- HeLa epithelial cells and 293T human embryo kidney cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and antibiotics (Life Technologies, Inc.). Mouse NIH-3T3 cells were grown in Dulbecco's modified Eagle's medium supplemented with 10% calf serum and antibiotics (Life Technologies, Inc.). Transfections were performed by the calcium precipitate method or lipofection (LipofectAMINE Plus; Life Technologies, Inc.). The overall amount of DNA in transfection mixtures was kept constant by the addition of pCDNA3. Preparation of cell lysates and immunoblotting were performed as described elsewhere (17). Briefly, for detection of endogenous beta -TrCP, 1 mg of protein lysates were immunoprecipitated with beta -TrCP antibody (1 µg), separated on 8% SDS-polyacrylamide gel electrophoresis, transferred onto a nitrocellulose membrane, and probed with beta -TrCP antibody at a 1:500 dilution. Membranes were developed with the ECL kit (Amersham Pharmacia Biotech) and exposed to film.

Loading of cell lysates on gels was normalized for protein concentration. The luciferase assay was performed using a kit (Promega), and the data were normalized per transfection efficiency.

Solid Phase Protein Kinase Activity Assays-- JNK and IKK activity in whole cell extracts (10 µg) was assessed in the solid phase kinase assay with bacterially expressed glutathione S-transferase-c-Jun (amino acids 5-89) or glutathione S-transferase-Ikappa B (amino acids 1-54) in the presence of [gamma -32P]ATP (50 cpm/fmol) as described elsewhere (37).

    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Cellular Stress-mediated Activation of JNK Up-regulates beta -TrCP mRNA and Protein Levels-- We have tested the effects of JNK on beta -TrCP levels by forced expression of N terminus truncated MEKK1 (Delta MEKK1), which is known as a very potent upstream activator of JNK pathway. As is evident from Fig. 1A, transfection of 293T human embryo kidney cells with the Delta MEKK1 construct led to a robust increase in the steady state levels of beta -TrCP mRNA, whereas the expression of the beta -TrCP close relative HOS (17) was hardly affected.


View larger version (27K):
[in this window]
[in a new window]
 
Fig. 1.   Activation of the JNK pathway elevates the steady state levels of beta -TrCP mRNA. The representative results of three independent experiments are shown. A, Northern blot analysis of RNA extracted from 293T cells 48 h after transfection with pCDNA3 or Delta MEKK1 plasmids (2 µg). B, Northern blot analysis of RNA extracted from 293T cells 48 h after transfection with the indicated constructs plasmids (5 µg each). The film is overexposed compared with A in order to show a moderate effect of MKK6D/D.

In the overexpression experiments, Delta MEKK1 was reported to activate JNK as well as IKK (38) and MEK (39). To investigate which of those pathways contribute to induction of beta -TrCP, we expressed the constructs encoding constitutively active IKK (IKKbeta SE (15)), activator of JNK (JNKKCAA (10)), activator of p38 (MKK6D/D (10)), and activator of mitogen-activated protein kinase (MEK1S218E,S222L, MEKEL (40)). We found that transfection of 293T cells with JNKKCAA but not with IKKbeta SE or MEKEL elevated the steady state levels of beta -TrCP. A moderate increase in beta -TrCP levels was observed after expression of MKK6D/D (Fig. 1B). These data suggest that activation of JNK (and, to some extent, the p38 kinase pathway) results in the induction of beta -TrCP.

JNK and p38 belong to a subfamily of stress-activated protein kinases, and their activities are drastically up-regulated in response to a variety of stress stimuli including oxidative and osmotic stress. Thus, we next tested whether cellular stress affects the expression of beta -TrCP. An oxidative stress caused by treatment of 293T cells with H2O2 resulted in an approximately 4-fold increase in the steady state levels of beta -TrCP mRNA (Fig. 2A). This increase was observed within 30 min and lasted up to 2 h. Similar extent and kinetics of the up-regulation of beta -TrCP mRNA levels were achieved by incubation of cells in the presence of tumor necrosis factor alpha  (TNFalpha ; 20 ng/ml).


View larger version (43K):
[in this window]
[in a new window]
 
Fig. 2.   Accumulation of beta -TrCP mRNA in response to stress. 293T cells were treated with H2O2 (100 µM; A) or UV (40 J/m2; B) and harvested at the indicated time points after the treatment. Total RNA was extracted and analyzed by Northern blot with the beta -TrCP and 7S probes. The representative results of three independent experiments are shown.

Irradiated 293T cells with UV led to even more robust (up to 8-10-fold) and prolonged (up to 8 h) elevation of the steady state levels of beta -TrCP mRNA (Fig. 2B). Comparable results were obtained in the cells treated with sorbitol (0.6 M) to induce a hyperosmotic shock.2 Altogether, these data provide the evidence that cellular stress and induction of stress-activated protein kinases up-regulate the levels of beta -TrCP mRNA. The induction of two major beta -TrCP mRNA species did not seem to be coordinate; the accumulation of a longer transcript was more pronounced in the stressed cells (Fig. 2, A and B). This observation may reflect an alteration of beta -TrCP mRNA processing in response to stress, although the exact nature of this phenomenon remains to be elucidated.

In order to follow up the stress-inducible changes in the beta -TrCP protein expression, we have developed a rabbit polyclonal antibody (see "Materials and Methods") as a probe for endogenous beta -TrCP. This antibody readily recognized recombinant beta -TrCP protein, whose expression was driven by cytomegalovirus-based vector in 293T human kidney cells or by baculovirus expression system in insect cells (Fig. 3A). The antibody specifically interacted with beta -TrCP but not with another F-box protein Fbx7 (Fig. 3B).


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 3.   Characterization of the polyclonal antibody against beta -TrCP and the effects of JNK activation and stress on the levels of endogenous beta -TrCP. A, the lysates from 293T cells transfected with pCDNA3 or beta -TrCP expression vector as well as the recombinant beta -TrCP produced by baculovirus infection in insect cells (beta TrCPrec., right lane) were separated on 8% SDS-polyacrylamide gel electrophoresis, transferred onto nitrocellulose membrane, and analyzed by immunoblotting with polyclonal antibody against beta -TrCP. B, the lysates from 293T cells transfected with the FLAG-tagged Fbx7 or beta -TrCP expression vector were separated on 8% SDS-polyacrylamide gel electrophoresis, transferred onto nitrocellulose membrane, and analyzed by immunoblotting with monoclonal antibody against FLAG tag (upper panel) or polyclonal antibody against beta -TrCP (lower panel). C, 293T cells were transfected with Delta MEKK1 (2 µg) and SEKAL (8 µg) as indicated. Forty-eight hours later, the cells were harvested, and the cell lysates were prepared and analyzed for the levels of beta -TrCP by immunoprecipitation followed by immunoblotting (panel I) and expression of Delta MEKK1 (panel II) and SEKAL (panel III) by direct immunoblotting as well as for activities of IKK (panel IV) and JNK (panel V) as described under "Materials and Methods." A representative result of three independent experiments is shown. D, 293T cells were treated with UV (40 J/m2), H2O2 (100 µM), or TNFalpha (20 ng/ml; R&D Systems). One hour after treatment, the cells were harvested, and the cell lysates were prepared and analyzed for the levels of beta -TrCP by immunoprecipitation and immunoblotting. A representative result of two independent experiments is shown.

Forced expression of Delta MEKK1 in 293T cells resulted in a robust activation of JNK (Fig. 3C, panel V), modest (if any) activation of IKK (Fig. 3C, panel IV), and noticeable accumulation of endogenous beta -TrCP protein (Fig. 3C, panel I). All of those effects of Delta MEKK1 were largely inhibited by co-expression of a dominant negative JNKK/SEK construct (SEKAL (41)). The control immunoblot analysis demonstrated that the effects of SEKAL could not be explained by changes in the truncated MEKK1 expression (Fig. 3C, panel II). Treatment of cells with physiological JNK inducers UV, H2O2, and TNFalpha also increased the steady state levels of beta -TrCP (Fig. 3D). These data indicate that cellular stress and stress-mediated activation of JNK pathway leads to an increase in the levels of beta -TrCP protein.

mRNA Stabilization as a Mechanism of JNK- and Cellular Stress-mediated Up-regulation of beta -TrCP-- The Wnt pathway was shown to elevate the beta -TrCP levels in a manner that is not dependent on beta -TrCP gene transcription. To investigate whether beta -TrCP transcription is required for induction of beta -TrCP by the JNK pathway, we have carried out a run-on assay with nuclei isolated from 293T cells transfected with constitutively active Delta MEKK1 or pCDNA3 plasmids. Expression of Delta MEKK1 led to a robust increase in transcription of c-jun, a well known downstream target of the JNK pathway (2, 3). We did not detect any corresponding increase in the rate of beta -TrCP transcription (Fig. 4A). These results suggest that activation of beta -TrCP gene promotor is not required for up-regulation of beta -TrCP by stress and JNK activation.


View larger version (36K):
[in this window]
[in a new window]
 
Fig. 4.   Induction of beta -TrCP by JNK does not require transcription of the beta -TrCP gene. A, nuclear run-on analysis of beta -TrCP, 7S, and c-jun transcription in the nuclei isolated from 293T cells 48 h after transfection with pCDNA3 or Delta MEKK1 vectors (10 µg each). The membranes were exposed for 3 h for c-jun or overnight for beta -TrCP and 7S. A representative of two independent experiments is shown. B, Northern blot analysis of RNA isolated from 293T cells transfected with 5 µg of either active JNKKCAA (3-h autoradiography exposure) or inactive JNKKAA (48-h exposure) and treated with actinomycin D (10 µg/ml) for the indicated time points. A representative of two independent experiments is shown.

Treatment of 293T cells (transfected with inactive JNKKAA) with actinomycin D to inhibit transcription allowed us to observe degradation of endogenous beta -TrCP mRNA within 2-4 h (Fig. 4B). In contrast to that, little beta -TrCP mRNA degradation was seen in the cells expressing constitutively active JNKKCAA (Fig. 4B). These data indicate that activation of JNK may lead to stabilization of beta -TrCP mRNA.

To further analyze the mechanisms underlying an increase in beta -TrCP levels by cellular stress and JNK activation, we utilized the expression of exogenous human cytomegalovirus-driven beta -TrCP construct containing an intact 3'-UTR in mouse NIH-3T3 cells. These cells did not express any amounts of endogenous beta -TrCP, which were detectable by Northern blot analysis with either human (Fig. 5A) or mouse (data not shown) probe. Treatment of NIH-3T3 cells, which express exogenous beta -TrCP, with H2O2 led to accumulation of beta -TrCP mRNA (Fig. 5A). Co-expression of constitutively active JNKKCAA (but not of inactive JNKKAA) also increased the steady state levels of exogenous beta -TrCP (Fig. 5B). Before finally concluding on a posttranscriptional mechanism of beta -TrCP induction, the effects of stress still needed to be tested in the absence of the cytomegalovirus-driven transcription. To this end, we have inhibited transcription by treating the transfected NIH 3T3 cells with actinomycin D and assessed the rate of degradation of the exogenously expressed beta -TrCP mRNA. This mRNA was found rather unstable in the nonstressed cells (with the estimated half-life of ~40 min). However, incubation of cells in the presence of both actinomycin D and H2O2 prevented the degradation of beta -TrCP-3'-UTR mRNA (Fig. 5C). Altogether, these findings strongly indicate that the cellular stress-mediated increase in beta -TrCP levels is realized through stabilization of beta -TrCP mRNA.


View larger version (25K):
[in this window]
[in a new window]
 
Fig. 5.   Stabilization of beta -TrCP mRNA by JNK activation and stress in NIH-3T3 cells. The representative results of two independent experiments are shown. A, Northern blot analysis of RNA extracted from NIH-3T3 cells 48 h after transfection with pCDNA3 or beta -TrCP-3'-UTR (4 µg) and 1 h after treatment with H2O2 (100 µM) as indicated. B, Northern blot analysis of RNA extracted from NIH-3T3 cells 30 h after co-transfection with pCDNA3, beta -TrCP-3'-UTR (2 µg), and either active JNKKCAA or inactive JNKKAA (2 µg each). C, NIH-3T3 cells were transfected with beta -TrCP-3'-UTR. Thirty hours later, the cells were treated with actinomycin D (ActD; 10 µg/ml; lanes 3-10). At the time point 0 (15 min after the addition of actinomycin D), H2O2 was added to the culture medium as indicated (100 µM). Cells were harvested at the indicated time points, and RNA was extracted and analyzed by Northern blot.

Activation of JNK Up-regulates NF-kappa B Transcriptional Activities-- Elevation of the endogenous levels of beta -TrCP may result in an increase in the efficiency of Ikappa B ubiquitination and degradation, leading to the activation of NF-kappa B-dependent transcription (31). We have indeed observed a cooperative effect of constitutively active IKK and JNKK on acceleration of Ikappa B degradation measured by pulse chase in 293T cells.2 It has been previously shown that Delta MEKK1 is capable of activating the NF-kappa B driven reporters under overexpression conditions (38, 42). To examine the possible effect of JNK-mediated accumulation of beta -TrCP on NF-kappa B activities, we chose the conditions under which JNK is activated by expression of its immediately upstream and most specific activator JNKK. In order to exclude any effects on IKK activities, we saturated Ikappa B phosphorylation by forced expression of constitutively active IKKSE. Expression of this construct in 293T cells readily elevated the activity of NF-kappa B-driven luciferase reporter. Remarkably, co-transfection of JNKKCAA resulted in further increase in NF-kappa B transcriptional activity in a dose-dependent manner (Fig. 6). Similar results were obtained in HeLa cells. We did not detect any effects of JNKKCAA on the activity of IKKSE measured in an immunokinase assay with recombinant bacterially expressed glutathione S-transferase-Ikappa Balpha as a substrate (data not shown). These data suggest that JNK cooperates with IKK in induction of NF-kappa B transcriptional activity and that JNK-mediated up-regulation of beta -TrCP may serve as a mechanism of this cooperation.


View larger version (12K):
[in this window]
[in a new window]
 
Fig. 6.   Activation of JNK contributes to NF-kappa B transcriptional activities. 293T cells were transfected with 2x-kappa B-luciferase (400 ng) and pRSV-beta -gal (100 ng) together with the indicated (in ng) amount of IKKbeta SE and JNKKCAA. Thirty hours later, the luciferase activity was measured. Normalized arbitrary unit values of two independent experiments (each in triplicate) are shown.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Activation of NF-kappa B by stress and proinflammatory cytokines requires that NF-kappa B be released from its cytoplasmic retention by Ikappa B. Ubiquitination and subsequent proteasome-dependent degradation of Ikappa B requires both phosphorylation of Ikappa B by IKK and recognition of phosphorylated Ikappa B by beta -TrCP/Fbw1a (27, 29, 30) or its relative protein HOS/Fbw1b (17, 43). Several lines of evidence suggest that the cellular levels of Fbw1 proteins are critical for Ikappa B ubiquitination. First, beta -TrCP basal expression is very low, and beta -TrCP protein is hardly detected by a direct immunoblotting analysis (Ref. 31 and this study). Second, the ubiquitination and degradation of Ikappa B is readily inhibited in living cells by squelching beta -TrCP with the phosphopeptides mimicking the phosphorylated Ikappa B (44) or by expression of F-box-deficient dominant negative beta -TrCP mutants (24, 26, 27-30). Third, an increase in beta -TrCP levels by Wnt signaling promotes the transcriptional activation of NF-kappa B in response to an increase in Ikappa B phosphorylation by constitutively active IKKbeta (31).

In this study, we have demonstrated that cellular stress and activation of JNK pathway results in accumulation of beta -TrCP via stabilization of beta -TrCP mRNA. The elevated levels of beta -TrCP together with activation of IKK and subsequent Ikappa B phosphorylation contributes to a rapid Ikappa B degradation and NF-kappa B nuclear translocation in response to stress (Fig. 7). Therefore, the findings reported here identify a mechanism underlying the cooperation between stress-induced activation of IKK and JNK pathways in the activation of NF-kappa B-dependent transcription. Moreover, activation of JNK by Dsh (32) may play a role in the induction of beta -TrCP by the Wnt pathway (31) in addition to beta -catenin/Tcf-dependent mechanisms (Fig. 7).


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 7.   A model for cooperation between stress-induced JNK and IKK in the activation of NF-kappa B. Both phosphorylation of Ikappa B by IKK and recognition of phosphorylated Ikappa B by the elevated levels of beta -TrCP contribute to Ikappa B degradation and NF-kappa B activation. Activation of JNK by Dsh may also contribute to induction of beta -TrCP by the Wnt pathway.

Simultaneous activation of JNK and NF-kappa B by stress and proinflammatory cytokines has been long reported and often attributed to the common components. Although several common signaling effectors (e.g. TRAF2 (45, 46), MEKK1 (38), and CIKS (47)) are known to signal to both JNK/p38 and IKK activation, little information is available about the cooperation of those signaling pathways. Activation of p38 kinase by salicylates was reported to inhibit Ikappa B degradation and NF-kappa B activation via suppression of IKK activities (48, 49). We observed only a very modest accumulation of beta -TrCP mRNA in response to the p38 pathway activation (Fig. 1B). It has been recently found that DNA binding and transcriptional activation of NF-kappa B induced by thioredoxin requires activation of JNK and can be inhibited by overexpression of the dominant negative JNKK/JNK constructs (50). These data are in agreement with our findings that JNK activation promotes NF-kappa B transcriptional activities. Coordinated effects of IKK and JNK activation on Ikappa B phosphorylation and the recognition of phosphorylated Ikappa B by SCFbeta -TrCP-Roc1 E3 ubiquitin protein ligase provide a good explanation for efficient activation of NF-kappa B by a broad spectrum of cellular stress stimuli.

Our findings also suggest that some of the important cellular functions of JNK may be attributed to its regulation of NF-kappa B transcriptional output. For example, there is a positive correlation between JNK and NF-kappa B activation in the regulation of apoptosis. In T lymphocytes, activation of both signaling pathways results in induction of apoptosis (51, 52). In some other cell types, both JNK and NF-kappa B are shown to hold antiapoptotic function. For example, X protein of hepatitis B virus inhibits Fas-mediated apoptosis and is associated with up-regulation of both stress-activated protein kinase/JNK (53) and NF-kappa B (54-56) pathways in hepatocytes. Expression of JNK2 is required to suppress apoptosis in human tumor cells MCF-7 and HCT116 (57). Activation of NF-kappa B was also shown to prevent apoptosis in these cells (58, 59). Both JNK and NF-kappa B prevent apoptosis induced by c-Myc overexpression in fibroblasts (60, 61).

However, the suggested beta -TrCP-dependent mechanism of cooperation between JNK and NF-kappa B pathways may not necessarily exist in all types of cells. Some cells (e.g. NIH-3T3) do not express detectable levels of endogenous beta -TrCP (Fig. 5), and, therefore, they are not capable of modulation of NF-kappa B activity by JNK through induction of beta -TrCP. Thus, one should not expect a universal concordance in JNK and NF-kappa B cellular functions including the regulation of apoptosis.

Cellular stress and JNK activation elevate the steady state levels of beta -TrCP in a transcription-independent manner. The finding that JNK up-regulates the levels of beta -TrCP via stabilization of its mRNA is not entirely surprising. Activation of the JNK pathway has been implicated in the stabilization of many short-lived mRNAs including interleukin-2 (10), interleukin-3 (12), vascular endothelial growth factor (14), and others. The effectors of stress, which mediate such stabilization are largely unknown. Stability of many short lived mRNAs, which contain AU-rich elements, is often controlled by HuR, the ubiquitously expressed member of the ELAV protein family (reviewed in Ref. 13). Analysis of the beta -TrCP mRNA sequence revealed three AU-rich elements, two of which are located in the 3'-UTR. Translocation of the nuclear HuR protein to the cytoplasm is suggested to constitute one of the mechanisms of HuR-mediated stabilization of p21CIP/WAF mRNA in response to stress (36). In addition to three AU-rich elements, beta -TrCP mRNA contains an ACUACUGCCCAGTTTCC sequence in its 3'-UTR. This sequence closely resembles a distal part of the JNK response element, which was found in the 5'-UTR of interleukin-2 mRNA and mediated its stabilization by Delta MEKK1 (11). YB-1 and nucleolin proteins were shown to bind to the JNK response element (11). Future studies will determine the role of these and other factors as well as AU-rich and JNK-response elements in the regulation of beta -TrCP mRNA stability.

Our data do not allow us to exclude the possibility that additional mechanisms of stress-inducible accumulation of beta -TrCP protein (e.g. protein stabilization) may exist. The exact modes of beta -TrCP induction by JNK are yet to be identified and future studies are required to further delineate the mechanisms of beta -TrCP-mediated cooperation between JNK and NF-kappa B activation.

    ACKNOWLEDGEMENTS

We thank Drs. M. Karin, R. Benarous, S. Aaronson, A. Minden, and J. Woodgett for the generous gifts of reagents. We thank Drs. V. Fried and H. Furneaux for critical suggestions and Dr. K. Spiegelman for help with the manuscript preparation.

    FOOTNOTES

* This study was supported in part by National Institutes of Health Grants CA 92900 (to S. Y. F.) and CA 76262 (to T. J. S.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

** To whom correspondence should be addressed: Dept. of Animal Biology, University of Pennsylvania, School of Veterinary Medicine, 3800 Spruce St., Rm. 161E VET, Philadelphia, PA 19104-6046. Tel.: 215-573-6949; Fax: 215-573-5188; E-mail: sfuks@vet.upenn.edu.

Published, JBC Papers in Press, May 24, 2001, DOI 10.1074/jbc.M100031200

2 V. Spiegelman and S. Fuchs, unpublished data.

    ABBREVIATIONS

The abbreviations used are: JNK, c-Jun N-terminal kinase(s); MEKK, mitogen-activated protein kinase kinase kinase; NF-kappa B, nuclear factor kappa B; Ikappa B, inhibitor of NF-kappa B; IKK, Ikappa B kinase(s); MKK/MEK, mitogen-activated protein kinase kinase; JNKK/SEK, JNK kinase; beta -TrCP, beta -transducin repeat-containing protein; HOS, homologue of Slimb; SCF, Skp1-cullin 1-F-box protein complex; Fbw, F-box/WD40 domain protein; TNFalpha , tumor necrosis factor alpha ; 3'-UTR, 3'-untranslated region; E3, ubiquitin-protein isopeptide ligase.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

1. Ronai, Z. (1999) Oncogene 18, 6084-6086
2. Davis, R. J. (1999) Biochem. Soc. Symp. 64, 1-12
3. Karin, M. (1999) J. Biol. Chem. 274, 27339-27342
4. Derijard, B., Raingeaud, J., Barrett, T., Wu, I. H., Han, J., Ulevitch, R. J., and Davis, R. J. (1995) Science 267, 682-685
5. Sanchez, I., Hughes, R. T., Mayer, B. J., Yee, K., Woodgett, J. R., Avruch, J., Kyriakis, J. M., and Zon, L. I. (1994) Nature 372, 794-798
6. Moriguchi, T., Toyoshima, F., Masuyama, N., Hanafusa, H., Gotoh, Y., and Nishida, E. (1997) EMBO J. 16, 7045-7053
7. Tournier, C., Whitmarsh, A. J., Cavanagh, J., Barrett, T., and Davis, R. J. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 7337-7342
8. Moriguchi, T., Toyoshima, F., Gotoh, Y., Iwamatsu, A., Irie, K., Mori, E., Kuroyanagi, N., Hagiwara, M., Matsumoto, K., and Nishida, E. (1996) J. Biol. Chem. 271, 26981-26988
9. Stein, B., Brady, H., Yang, M. X., Young, D. B., and Barbosa, M. S. (1996) J. Biol. Chem. 271, 11427-11433
10. Chen, C. Y., Del Gatto-Konczak, F., Wu, Z., and Karin, M. (1998) Science 280, 1945-1949
11. Chen, C. Y., Gherzi, R., Andersen, J. S., Gaietta, G., Jurchott, K., Royer, H. D., Mann, M., and Karin, M. (2000) Genes Dev. 14, 1236-1248
12. Ming, X. F., Kaiser, M., and Moroni, C. (1998) EMBO J. 17, 6039-6048
13. Mitchell, P., and Tollervey, D. (2000) Curr. Opin. Genet. Dev. 10, 193-198
14. Pages, G., Berra, E., Milanini, J., Levy, A. P., and Pouyssegur, J. (2000) J. Biol. Chem. 275, 26484-26491
15. Verma, I. M., and Stevenson, J. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 11758-11760
16. Margottin, F., Bour, S. P., Durand, H., Selig, L., Benichou, S., Richard, V., Thomas, D., Strebel, K., and Benarous, R. (1998) Mol. Cell 1, 565-574
17. Fuchs, S. Y., Chen, A., Xiong, Y., Pan, Z. Q., and Ronai, Z. (1999) Oncogene 18, 2039-2046
18. Deshaies, R. J. (1999) Annu. Rev. Cell Dev. Biol. 15, 435-467
19. Karin, M., and Ben-Neriah, Y. (2000) Annu. Rev. Immunol. 18, 621-663
20. Laney, J. D., and Hochstrasser, M. (1999) Cell 97, 427-430
21. Cenciarelli, C., Chiaur, D. S., Guardavaccaro, D., Parks, W., Vidal, M., and Pagano, M. (1999) Curr. Biol. 9, 1177-1179
22. Bai, C., Sen, P., Hofmann, K., Ma, L., Goebl, M., Harper, J. W., and Elledge, S. J. (1996) Cell 86, 263-274
23. Winston, J. T., Koepp, D. M., Zhu, C., Elledge, S. J., and Harper, J. W. (1999) Curr. Biol. 9, 1180-1182
24. Hatakeyama, S., Kitagawa, M., Nakayama, K., Shirane, M., Matsumoto, M., Hattori, K., Higashi, H., Nakano, H., Okumura, K., Onoe, K., Good, R. A., and Nakayama, K. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 3859-3863
25. Hattori, K., Hatakeyama, S., Shirane, M., Matsumoto, M., and Nakayama, K. (1999) J. Biol. Chem. 274, 29641-29647
26. Kroll, M., Margottin, F., Kohl, A., Renard, P., Durand, H., Concordet, J. P., Bachelerie, F., Arenzana-Seisdedos, F., and Benarous, R. (1999) J. Biol. Chem. 274, 7941-7945
27. Spencer, E., Jiang, J., and Chen, Z. J. (1999) Genes Dev. 13, 284-294
28. Suzuki, H., Chiba, T., Kobayashi, M., Takeuchi, M., Suzuki, T., Ichiyama, A., Ikenoue, T., Omata, M., Furuichi, K., and Tanaka, K. (1999) Biochem. Biophys. Res. Commun. 256, 127-132
29. Winston, J. T., Strack, P., Beer-Romero, P., Chu, C. Y., Elledge, S. J., and Harper, J. W. (1999) Genes Dev. 13, 270-283
30. Yaron, A., Hatzubai, A., Davis, M., Lavon, I., Amit, S., Manning, A. M., Andersen, J. S., Mann, M., Mercurio, F., and Ben-Neriah, Y. (1998) Nature 396, 590-594
31. Spiegelman, V. S., Slaga, T. J., Pagano, M., Minamoto, T., Ronai, Z., and Fuchs, S. Y. (2000) Mol. Cell 5, 877-882
32. Boutros, M., Paricio, N., Strutt, D. I., and Mlodzik, M. (1998) Cell 94, 109-118
33. Zandi, E., Rothwarf, D. M., Delhase, M., Hayakawa, M., and Karin, M. (1997) Cell 91, 243-252
34. DiDonato, J. A., Hayakawa, M., Rothwarf, D. M., Zandi, E., and Karin, M. (1997) Nature 388, 548-554
35. Deleted in proof
36. Wang, W., Furneaux, H., Cheng, H., Caldwell, M. C., Hutter, D., Liu, Y., Holbrook, N., and Gorospe, M. (2000) Mol. Cell. Biol. 20, 760-769
37. Adler, V., Yin, Z., Fuchs, S. Y., Benezra, M., Rosario, L., Tew, K. D., Pincus, M. R., Sardana, M., Henderson, C. J., Wolf, C. R., Davis, R. J., and Ronai, Z. (1999) EMBO J. 18, 1321-1334
38. Lee, F. S., Hagler, J., Chen, Z. J., and Maniatis, T. (1997) Cell 88, 213-222
39. Xu, S., Robbins, D., Frost, J., Dang, A., Lange-Carter, C., and Cobb, M. H. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 6808-6812
40. Jaaro, H., Rubinfeld, H., Hanoch, T., and Seger, R. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 3742-3747
41. Tibbles, L. A., Ing, Y. L., Kiefer, F., Chan, J., Iscove, N., Woodgett, J. R., and Lassam, N. J. (1996) EMBO J. 15, 7026-7035
42. Nemoto, S., DiDonato, J. A., and Lin, A. (1998) Mol. Cell. Biol. 18, 7336-7343
43. Suzuki, H., Chiba, T., Suzuki, T., Fujita, T., Ikenoue, T., Omata, M., Furuichi, K., Shikama, H., and Tanaka, K. (2000) J. Biol. Chem. 275, 2877-2884
44. Yaron, A., Gonen, H., Alkalay, I., Hatzubai, A., Jung, S., Beyth, S., Mercurio, F., Manning, A. M., Ciechanover, A., and Ben-Neriah, Y. (1997) EMBO J. 16, 6486-6494
45. Liu, Z. G., Hsu, H., Goeddel, D. V., and Karin, M. (1996) Cell 87, 565-576
46. Shi, C. S., Leonardi, A., Kyriakis, J., Siebenlist, U., and Kehrl, J. H. (1999) J. Immunol. 163, 3279-3285
47. Leonardi, A., Chariot, A., Claudio, E., Cunningham, K., and Siebenlist, U. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 10494-10499
48. Schwenger, P., Alpert, D., Skolnik, E. Y., and Vilcek, J. (1998) Mol. Cell. Biol. 18, 78-84
49. Alpert, D., and Vilcek, J. (2000) J. Biol. Chem. 275, 10925-10929
50. Das, K. C. (2001) J. Biol. Chem. 276, 4662-4670
51. Kasibhatla, S., Brunner, T., Genestier, L., Echeverri, F., Mahboubi, A., and Green, D. R. (1998) Mol. Cell 1, 543-551
52. Kasibhatla, S., Tailor, P., Bonefoy-Berard, N., Mustelin, T., Altman, A., and Fotedar, A. (1999) Mol. Cell. Biol. 19, 2021-2031
53. Diao, J., Khine, A. A., Sarangi, F., Hsu, E., Iorio, C., Tibbles, L. A., Woodgett, J. R., Penninger, J., and Richardson, C. D. (2000) J. Biol. Chem. 276, 8328-8340
54. Chirillo, P., Falco, M., Puri, P. L., Artini, M., Balsano, C., Levrero, M., and Natoli, G. (1996) J. Virol. 70, 641-646
55. Kekule, A. S., Lauer, U., Weiss, L., Hofschneider, P. H., and Koshy, R. (1992) Arch. Virol. Suppl. 4, 63-64
56. Weil, R., Sirma, H., Giannini, C., Kremsdorf, D., Bessia, C., Dargemont, C., Brechot, C., and Israel, A. (1999) Mol. Cell. Biol. 19, 6345-6354
57. Potapova, O., Gorospe, M., Dougherty, R. H., Dean, N. M., Gaarde, W. A., and Holbrook, N. J. (2000) Mol. Cell. Biol. 20, 1713-1722
58. Nakshatri, H., Bhat-Nakshatri, P., Martin, D. A., Goulet, R. J., Jr., and Sledge, G. W., Jr. (1997) Mol. Cell. Biol. 17, 3629-3639
59. Zwacka, R. M., Stark, L., and Dunlop, M. G. (2000) J. Gene Med. 2, 334-343
60. Romashkova, J. A., and Makarov, S. S. (1999) Nature 401, 86-90
61. Mazars, A., Tournigand, C., Mollat, P., Prunier, C., Ferrand, N., Bourgeade, M. F., Gespach, C., and Atfi, A. (2000) Oncogene 19, 1277-1287


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
S. H. Ki, M. J. Choi, C. H. Lee, and S. G. Kim
G{alpha}12 Specifically Regulates COX-2 Induction by Sphingosine 1-Phosphate: ROLE FOR JNK-DEPENDENT UBIQUITINATION AND DEGRADATION OF I{kappa}B{alpha}
J. Biol. Chem., January 19, 2007; 282(3): 1938 - 1947.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
D. Hargett, S. Rice, and S. L. Bachenheimer
Herpes Simplex Virus Type 1 ICP27-Dependent Activation of NF-{kappa}B
J. Virol., November 1, 2006; 80(21): 10565 - 10578.
[Abstract] [Full Text] [PDF]


Home page
Physiol. GenomicsHome page
H.-Y. Cho, A. E. Jedlicka, R. Clarke, and S. R. Kleeberger
Role of Toll-like receptor-4 in genetic susceptibility to lung injury induced by residual oil fly ash
Physiol Genomics, June 16, 2005; 22(1): 108 - 117.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
R. S. Abraham, K. V. Ballman, A. Dispenzieri, D. E. Grill, M. K. Manske, T. L. Price-Troska, N. G. Paz, M. A. Gertz, and R. Fonseca
Functional gene expression analysis of clonal plasma cells identifies a unique molecular profile for light chain amyloidosis
Blood, January 15, 2005; 105(2): 794 - 803.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
A. Ougolkov, B. Zhang, K. Yamashita, V. Bilim, M. Mai, S. Y. Fuchs, and T. Minamoto
Associations Among {beta}-TrCP, an E3 Ubiquitin Ligase Receptor, {beta}-Catenin, and NF-{kappa}B in Colorectal Cancer
J Natl Cancer Inst, August 4, 2004; 96(15): 1161 - 1170.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Y. Zhang and F. Chen
Reactive Oxygen Species (ROS), Troublemakers between Nuclear Factor-{kappa}B (NF-{kappa}B) and c-Jun NH2-terminal Kinase (JNK)
Cancer Res., March 15, 2004; 64(6): 1902 - 1905.
[Abstract] [Full Text] [PDF]